The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

前列腺癌 医学 阉割 癌症 肿瘤科 癌症研究 内科学 前列腺 激素
作者
Petra Deegen,Oliver S. Thomas,Olivier Nolan-Stevaux,Shyun Li,Joachim Wahl,Pamela Bogner,Famke Aeffner,Matthias Friedrich,Michael Z. Liao,Katja Matthes,Doris Rau,Benno Rattel,Tobias Raum,Peter Kufer,Angela Coxon,Julie M. Bailis
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:27 (10): 2928-2937 被引量:87
标识
DOI:10.1158/1078-0432.ccr-20-3725
摘要

Abstract Purpose: Metastatic castration-resistant prostate cancer (mCRPC) remains a disease with high unmet medical need, as most patients do not achieve durable response with available treatments. Prostate-specific membrane antigen (PSMA) is a compelling target for mCRPC. It is highly expressed by primary and metastatic prostate cancer cells, with increased expression after progression on androgen deprivation therapy. Experimental Design: We developed AMG 160, a half-life extended, bispecific T-cell engager immuno-oncology therapy that binds PSMA on prostate cancer cells and cluster of differentiation 3 on T cells for treatment of mCRPC. AMG 160 was evaluated in vitro and in mCRPC xenograft models. AMG 160 tolerability was assessed in nonhuman primates (NHP). AMG 160 activity as monotherapy and in combination with a PSMA-imaging agent, novel hormonal therapy, and immune checkpoint blockade was evaluated. Results: AMG 160 induces potent, specific killing of PSMA-expressing prostate cancer cell lines in vitro, with half-maximal lysis of 6–42 pmol/L. In vivo, AMG 160 administered weekly at 0.2 mg/kg engages T cells administered systemically and promotes regression of established 22Rv-1 mCRPC xenograft tumors. AMG 160 is compatible with the imaging agent gallium 68–labeled PSMA-11, and shows enhanced cytotoxic activity when combined with enzalutamide or an anti-programmed death-1 antibody. AMG 160 exhibits an extended half-life and has an acceptable safety profile in NHPs. Conclusions: The preclinical characterization of AMG 160 highlights its potent antitumor activity in vitro and in vivo, and its potential for use with known diagnostic or therapeutic agents in mCRPC. These data support the ongoing clinical evaluation of AMG 160 in patients with mCRPC. See related commentary by Kamat et al., p. 2675
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
慕青应助科研通管家采纳,获得10
1秒前
1秒前
1秒前
默默小鸽子完成签到,获得积分10
1秒前
英俊的铭应助科研通管家采纳,获得10
1秒前
汉堡包应助科研通管家采纳,获得10
1秒前
妩媚的海应助科研通管家采纳,获得50
1秒前
shusen完成签到,获得积分10
1秒前
打打应助科研通管家采纳,获得10
1秒前
Hello应助科研通管家采纳,获得10
1秒前
打打应助科研通管家采纳,获得10
1秒前
小蘑菇应助科研通管家采纳,获得10
1秒前
动听导师发布了新的文献求助10
2秒前
量子星尘发布了新的文献求助10
2秒前
2秒前
大臭发布了新的文献求助10
3秒前
古德毛宁发布了新的文献求助10
3秒前
染染完成签到,获得积分10
3秒前
Xide发布了新的文献求助10
3秒前
4秒前
坚强的刺猬完成签到,获得积分10
4秒前
qian应助白白采纳,获得10
4秒前
4秒前
情怀应助白白采纳,获得10
4秒前
彭伟盼完成签到,获得积分20
5秒前
5秒前
完美的书本完成签到,获得积分10
5秒前
热心市民小红花应助daijk采纳,获得10
5秒前
5秒前
5秒前
5秒前
科研小白完成签到,获得积分10
6秒前
一一发布了新的文献求助10
6秒前
7秒前
美丽谷槐完成签到,获得积分10
7秒前
魏然发布了新的文献求助10
7秒前
7秒前
CipherSage应助李盛男采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Research Methods for Business: A Skill Building Approach, 9th Edition 500
Social Work and Social Welfare: An Invitation(7th Edition) 410
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6054599
求助须知:如何正确求助?哪些是违规求助? 7879152
关于积分的说明 16283648
捐赠科研通 5199861
什么是DOI,文献DOI怎么找? 2782391
邀请新用户注册赠送积分活动 1765143
关于科研通互助平台的介绍 1646451